

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 26, 2004, 01:42:25 ; Search time 137 Seconds
(Without alignments)
1492.378 Million cell updates/sec

Title: US-09-805-020-72

Perfect score: 3506
Sequence: 1 MSFPLRIGLSNFDGSGSQSC.....LVSFLFLLVSLVNHVANDYY 648

Scoring table: BLOSUM62
Gapcp 10.0 , Gapext 0.5

Minimum DB seq length: 0
Maximum DB seq length: 200000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Searched:

1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters:

1017041

SPREMBL_25:
1: sp_archaea:
2: sp_bacteria:
3: sp_fungi:
4: sp_human:
5: sp_invertebrate:
6: sp_mammal:
7: sp_micr:
8: sp_organelle:
9: sp_plage:
10: sp_plant:
11: sp Rodent:
12: sp_virus:
13: sp_vertebrate:
14: sp_unclassified:
15: sp_rvirus:
16: sp_bacteriap:
17: sp_archaeap:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	284	81.1	571	11 Q8CAV6
2	2293	65.4	469	11 Q8C3L7
3	2100	60.5	683	13 Q7SZH8
4	2045.5	58.3	683	13 Q7SZH7
5	1757	57.6	676	4 Q8EXJ6
6	1666.5	44.7	464	11 Q920N9
7	1491	42.5	487	11 Q80UN7
8	1447	41.3	724	5 O61225
9	1345	38.4	763	5 O62569
10	1290.5	35.6	754	5 Q8MB6
11	1247.5	35.4	683	11 Q8K2KB
12	1235	35.2	661	5 Q8NE03
13	1166.5	33.3	670	13 Q7SY24

17	1160	33.1	670	13 Q8JFPZ9	Q8Jfz9 fugu rubrip
18	1145	32.7	756	5 O61224	O61224 scypho raph
19	1144.5	32.6	680	5 P0980	P0980 caenorhabdi
20	1143.5	32.6	680	5 Q8mQ88	Q8mQ88 caenorhabdi
21	1144.5	32.6	682	5 Q8mQ87	Q8mQ87 caenorhabdi
22	1144.5	32.6	936	5 P0981	P0981 caenorhabdi
23	1143.5	32.6	936	5 Q9024	Q9024 caenorhabdi
24	1129	32.2	668	13 Q7T2C5	Q7T2C5 brachydanio
25	1097	31.3	670	5 O01715	O01715 hydra attenuata
26	1075.5	30.7	674	5 O01716	O01716 hydra attenuata
27	1070.5	30.5	554	5 Q5IT78	Q5IT78 drotophila
28	1067	30.4	673	5 O2567	O62567 suberites d
29	998	28.5	677	5 O6997	O96997 sedi cyclo
30	975	27.8	685	5 O76850	O76850 calliphora
31	949.5	27.1	1035	3 Q862V2	Q862V2 pichia past
32	892	25.4	1161	3 Q8J213	Q8J213 kluveromyce
33	885	25.2	1157	3 Q8H110	Q8H110 blunaria gr
34	883	25.2	1194	3 Q97792	Q97792 sporothrix
35	871.5	24.9	1170	3 Q8DWT5	Q8DWT5 bottysis ci
36	860.5	24.5	1185	3 Q873Y9	Q873Y9 leptosphaera
37	857	24.4	1136	3 Q8Hgk8	Q8Hgk8 tubar boch
38	853	24.3	1182	3 Q877C1	Q877C1 magnaporthe
39	850	24.2	1187	5 O96942	O96942 rhadocarpus
40	848.5	24.2	447	5 Q86M17	Q86M17 branchiosco
41	845	24.1	991	3 Q86VF6	Q86VF6 tuber magna
42	775	22.1	542	13 Q80115	Q80115 scyliorhinus
43	739.5	21.1	606	5 Q8V782	Q8V782 drosophila
44	733.5	21.1	606	5 Q8GS23	Q8GS23 drosophila
45	739.5	21.1	606	5 Q8mt38	Q8mt38 drosophila

Databse :

ALIGNMENTS

RESULT 1

PRELIMINARY; PRT; 571 AA.

ID Q8CAV6 PRELIMINARY; PRT; 571 AA.
ID Q8CAV6; Created)
DT 01-MAR-2003 (TREMBBLE. 23, Last sequence update)

DT 01-OCT-2003 (TREMBBLE. 25, Last annotation update)
DE Protein kinase C.

GN A130055A12Rik.

Mus musculus (Mouse).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Buteraria; Rodentia; Sciurognathi; Muridae; Murinae; Mus; NCBI_TaxID:10997; [1]

SEQUENCE FROM N.A.

RP STRAIN=C57BL/6J; TISSUE=Thymus;
RK MEDLINE=22354683; PubMed=12466851;

RA THE RIKEN Genome Exploration Research Group Phase I & II Team;
RT Analysis of the mouse transcriptome based on functional annotation of full-length cDNAs.;
RT Nature 420:563-573 (2002).

RL EMBL; MGI; 2442365; AL30035112Rik.

DR MGI; MGI:2442365; AL30035112Rik.

DR GO; GO:000524; P:ATP binding; IEA.

DR GO; GO:0005489; P:electrostatics transporter activity; IEA.

DR GO; GO:000674; P:protein serine/threonine kinase activity; IEA.

DR GO; GO:0004713; P:protein tyrosine kinase activity; IEA.

DR GO; GO:0007242; P:intracellular signaling cascade; IEA.

DR GO; GO:000468; P:protein amino acid phosphorylation; IEA.

DR InterPro; IPR00973; C2 CalB.

DR InterPro; IPR00345; CYC-C heme BS.

DR InterPro; IPR00219; DAG_Pe-Bind.

DR InterPro; IPR000719; Prot kinase.

DR InterPro; IPR002290; Ser_Thr_Pkinase.

DR InterPro; IPR008271; Ser_Thr_Pkin_AS.

DR InterPro; IPR001245; Tyr_Pkinase.

DR InterPro; IPR00130; DAG_Pe-Bind; 2.

DR Pfam; PF00069; kinase; 1.
 DR PRINTS; PR00008; DAGPE DOMAIN.
 DR PRODOM; PR000001; Prot_kinase; 1.
 DR SMART; SMO0109; C1; 2.
 DR SMART; SMO0219; TYRCK; 1.
 DR PROSITE; PS00109; CYTOCHROME C; 1.
 DR PROSITE; PS00479; DAG PE BIND DOM; 1; 2.
 DR PROSITE; PS00081; DAG PE BIND DOM; 2; 2.
 DR PROSITE; PS00107; PROTEIN KINASE ATP; 1.
 DR PROSITE; PS50011; PROTEIN KINASE DOM; 1.
 DR PROSITE; PS00108; PROTEIN KINASE_ST; 1.
 DR SEQUENCE; 571 AA; 64932 MW; T10ED91673EA3C59 CRC64;

Query Match 81.1%; Score 2844; DB 11; Length 571;
 Best Local Similarity 94.5%; Pred. No. 7e-266;
 Matches 520; Conservative 16; Mismatches 14; Indels 0; Gaps 0;
 Pairs 1
 1 MSPLFRIGLSNFDGCGSCQSCQS COGEBAVPYCAVLKVEYESENGQWYIOKKPTMPPWDSTP 60
 1 MSPLFRIGLSNFDGCGTCACCOGEAVPYCAVLKVEYESENGQWYIOKKPTMPPWDSTP 60

QY 61 DAHINKRVMQIVKGKDVLISSETVELSLAERGRKKRKTEWLEKPKQGRMLNAR 120
 61 DAHINKRVMQIVKGKDVLISSETVELSLAERGRKKRKTEWLEKPKQGRMLNAR 120

Db 121 YFLEMSTDKDNEFETEGFFALHORGAIAKQAKVHVKCIEFTATFPQOPTFCVSHEFV 180
 121 YFLEMSTDKDNEFETEGFFALHORGAIAKQAKVHVKCIEFTATFPQOPTFCVSHEFV 180

QY 121 YFLEMSTDKDNEFETEGFFALHORGAIAKQAKVHVKCIEFTATFPQOPTFCVSHEFV 180
 121 YFLEMSTDKDNEFETEGFFALHORGAIAKQAKVHVKCIEFTATFPQOPTFCVSHEFV 180

Db 181 WGLANKQGYOCROCNAAIHKCKIDKVIAKCTGSAINSRTEWMHKERFKIDMPHRKFVNYK 240
 181 WGLANKQGYOCROCNAAIHKCKIDKVIAKCTGSAINSRTEWMHKERFKIDMPHRKFVNYK 240

QY 241 SPTFCERGTGLIWGLARGLQGKCDACGMVHRCQTKVANLIGINGQKLMALAMESTQQ 300
 241 SPTFCERGTGLIWGLARGLQGKCDACGMVHRCQTKVANLIGINGQKLMALAMESTQQ 300

Db 301 ARCLRDPEQIREGPYEGIGLPSIKNEARPCLPPTGKREBQGKISWESPLDEVDKMLHP 350
 301 ARCLRDPEQIREGPYEGIGLPSIKNEARPCLPPTGKREBQGKISWESPLDEVDKMLHP 350

Db 301 ARSLRSDSEHIFREGPVEIGLICLSTKNTETPRCPVTPGKREBQGKISWSDPGNSKSAGPP 360
 301 ARSLRSDSEHIFREGPVEIGLICLSTKNTETPRCPVTPGKREBQGKISWSDPGNSKSAGPP 360

QY 361 EPFLNKERPSLQIKLKIEDPFILHKMKGKSGKVKLAEEFKKTNQPAIKALKKQVLMDD 420
 361 EPFLNKERPSLQIKLKIEDPFILHKMKGKSGKVKLAEEFKKTNQPAIKALKKQVLMDD 420

Db 421 DVECTMVERKVLISLAWHEPFTHMFCPTQFENLFPVMEYLNGDLMLHQSCKFPLSR 480
 421 DVECTMVERKVLISLAWHEPFTHMFCPTQFENLFPVMEYLNGDLMLHQSCKFPLSR 480

QY 481 ATFYAAEILQLQPLHSKGVTYRDKLUDNLIDKQGHKTAADFQCKENNLGDAKNTFC 540
 481 ATFYAAEILQLQPLHSKGVTYRDKLUDNLIDKQGHKTAADFQCKENNLGDAKNTFC 540

Db 541 GTPDYIAPEI 550
 541 GTPDYIAPEI 550

Db 541 GIPDYIAPEV 550
 541 GIPDYIAPEV 550

RESULT 2

Q8C3L7 PRELIMINARY; PRT; 469 AA.

ID Q8C3L7; 01-MAR-2003 (T-EMBL; 23, Created)
 DT 01-MAR-2003 (T-EMBL; 23, Last Sequence update)
 DT 01-OCT-2003 (T-EMBL; 25, Last annotation update)

DB Protein kinase C.
 GN AL30051A2RZK.

Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Buteraria; Rodentia; Sciuromorpha; Muridae; Murinae; Mus.
 OC NCBI_TAXID:10090; [1]

SEQUENCER FROM N_A.
 RP STRAIN=C57BL/6J; TISSUE=Kidney;
 RC MEDLINE=22354683; PubMed=12466851;
 RX RA The RIKEN Genome Exploration Research Group Phase I & II Team;
 RT "Analyses of the mouse transcriptome based on functional annotation of
 RL 60,770 full-length cDNAs";
 Nature 420:563-73 (2002).
 DR EMBL; AK08546; BAC9469_1;
 DR MGDB; MGCI:2442367; AL3003512Rik.
 DR GO; GO_000524; F:ATP binding; IEA.
 DR GO; GO_0005489; F:electron transporter activity; IEA.
 DR GO; GO_0004672; F:protein kinase heme BS.
 DR InterPro; IPR00345; Cytc heme BS.
 DR InterPro; IPR002219; DAG PE-bind.
 DR InterPro; IPR00719; Prot_kinase.
 DR Pfam; PF00130; DAG PE-bind; 2.
 DR Pfam; PF00069; kinase; 1.
 DR PRINTS; PR00008; DAGPE DOMAIN.
 DR PRODOM; PR00001; Prot_kinase; 1.
 DR SMART; SMO0109; C1; 2.
 DR PROSITE; PS00107; DAG PE-bind.
 DR PROSITE; PS00479; DAG PE BIND DOM; 1; 2.
 DR PROSITE; PS00081; DAG PE BIND DOM; 2; 2.
 DR PROSITE; PS00107; PROTEIN KINASE ATP; 1.
 DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
 DR SEQUENCE; 469 AA; 53543 MW; 6F3D50C4DC2DE1A2 CRC64;

Query Match 65.4%; Score 2293; DB 11; Length 469;
 Best Local Similarity 90.5%; Pred. No. 1.3e-196;
 Matches 419; Conservative 22; Mismatches 22; Indels 0; Gaps 0;
 Pairs 1
 1 MSPLFRIGLSNFDGCGSCQSCQS COGEBAVPYCAVLKVEYESENGQWYIOKKPTMPPWDSTP 60
 1 MSPLFRIGLSNFDGCGTCACCOGEAVPYCAVLKVEYESENGQWYIOKKPTMPPWDSTP 60

QY 61 DAHINKRVMQIVKGKDVLISSETVELSLAERGRKKRKTEWLEKPKQGRMLNPR 120
 61 DAHINKRVMQIVKGKDVLISSETVELSLAERGRKKRKTEWLEKPKQGRMLNPR 120

Db 121 YFLEMSTDKDNEFETEGFFALHORGAIAKQAKVHVKCIEFTATFPQOPTFCVSHEFV 180
 121 YFLEMSTDKDNEFETEGFFALHORGAIAKQAKVHVKCIEFTATFPQOPTFCVSHEFV 180

QY 181 WGLANKQGYOCROCNAAIHKCKIDKVIAKCTGSAINSRTEWMHKERFKIDMPHRKFVNYK 240
 181 WGLANKQGYOCROCNAAIHKCKIDKVIAKCTGSAINSRTEWMHKERFKIDMPHRKFVNYK 240

Db 241 SPTFCERGTGLIWGLARGLQGKCDACGMVHRCQTKVANLIGINGQKLMALAMESTQQ 300
 241 SPTFCERGTGLIWGLARGLQGKCDACGMVHRCQTKVANLIGINGQKLMALAMESTQQ 300

QY 301 ARCLRDPEQIREGPYEGIGLPSIKNEARPCLPPTGKREBQGKISWESPLDEVDKMLHP 360
 301 ARCLRDPEQIREGPYEGIGLPSIKNEARPCLPPTGKREBQGKISWESPLDEVDKMLHP 360

Db 301 ARSLRSDSEHIFREGPVEIGLICLSTKNTETPRCPVTPGKREBQGKISWSDPGNSKSAGPP 360
 301 ARSLRSDSEHIFREGPVEIGLICLSTKNTETPRCPVTPGKREBQGKISWSDPGNSKSAGPP 360

QY 361 EPFLNKERPSLQIKLKIEDPFILHKMKGKSGKVKLAEEFKKTNQPAIKALKKQVLMDD 420
 361 EPFLNKERPSLQIKLKIEDPFILHKMKGKSGKVKLAEEFKKTNQPAIKALKKQVLMDD 420

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

M protein - protein search, using sw model

run on: March 25, 2004, 23:31:44 ; search time 140 Seconds
(database: (without alignment))
core table: BLOSUM62
Gapop 10.0 , Gapext 0.5
searched: 1586107 seqs, 282547505 residues
total number of hits satisfying chosen parameters: 1586107

maximum DB seq length: 0
maximum DB seq length: 200000000

post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

database : A_Geneseq_20Jan04:
1: geneseqp1980s: *
2: geneseqp1990s: *
3: geneseqp2000s: *
4: geneseqp2001s: *
5: geneseqp2002s: *
6: geneseqp2003s: *
7: geneseqp2003bs: *
8: geneseqp2004s: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Query Match length	DB ID	Description
1	3506	100.0	648	ABG79705
2	3344	95.4	615	ABG79708
3	3337	95.2	706	ABG62870
4	3337	94.9	706	ABP56907
5	3327	94.9	706	ABB60640
6	3327	94.9	706	ABR63656
7	2057.5	58.7	673	ADE57523
8	2037.5	58.1	676	ABG48037
9	1499	42.8	704	AAV91091
10	1499	42.8	704	AAV91091
11	1343	38.3	567	AAY55507
12	1343	38.3	567	AAB03687
13	1298.5	37.0	737	ADE57533
14	1298.5	37.0	737	AAD01490
15	1298.5	37.0	737	ADE57469
16	1298.5	37.0	737	ADE57541
17	1298.5	37.0	737	ADE57534
18	1298.5	37.0	737	ADE57533
19	1298.5	37.0	737	ADE57537
20	1298.5	37.0	737	ADE57529
21	1296.5	37.0	737	ADA50073
22	1296.5	37.0	737	AEE39167
23	1290.5	36.8	737	ADE57531
24	1290.5	36.8	737	ADE57532
25	1290.5	36.8	737	ADE57535

RESULT 1

ID	Description
ABG79705;	
XX	
AC	
XX	
DT	15-NOV-2002 (first entry)
XX	
DB	Tumour involved gene (TIG) splice variant protein, NY-36.
XX	
KW	Human; splice variant; tumour-involved gene; TIG; pharmacutical composition; cancer; diagnostic; tumour; gene therapy; endothelial cell; cell differentiation; cell proliferation; apoptosis; gene therapy.
XX	
OS	Homo sapiens.
XX	
PN	US2002086384-A1.
XX	
PD	04-JUL-2002.
XX	
PF	13-MAR-2001; 2001US-00805020.
XX	
PR	14-MAR-2000; 2000IL-00135402.
PR	16-MAY-2000; 2000IL-00136154.
XX	
PA	(LEVNI /) LEVINE Z.
PA	(DAVI /) DAVID A.
PA	(ROMA /) ROMANO C.
PA	(BERN /) BERNSTEIN J.
XX	
PI	Levine Z, David A, Romano C, Bernstein J;
XX	
DR	WPI; 2002-635679/68.
DR	N-PADB; ABS6235.
XX	
PT	Novel nucleic acid sequence, which is an alternative splicing variant of tumor involved genes, useful for detecting cancer, predisposition to cancer, for evaluating cancer state and in gene therapy for treating cancer.
CC	The invention discloses isolated human nucleic acid alternative splicing variants that are all tumor-involved genes (TIGs). The nucleic acids and polypeptides are useful for determining the level of a nucleic acid or polypeptide in a biological sample, for detecting a variant nucleic acid or polypeptide in a biological sample, for determining the level
CC	Claim 4; Page 105-107; 180pp; English.
CC	

CC of variant nucleic acid or polypeptide sequences in a biological sample
 CC and for determining the ratio between the level of variant sequence in a
 CC first biological sample and the level of the original sequence from which
 CC the variant has been varied by alternative splicing in a second
 CC biological sample and for raising antibodies. A pharmaceutical
 composition comprising a carrier and the nucleic acid, is useful for
 treating diseases (e.g. cancer) that can be ameliorated or cured by
 increasing or decreasing the level of the encoded protein. The nucleic
 acids are also useful for diagnostic purposes, especially for detecting
 cancer or a predisposition to cancer, for evaluating the state or
 aggressiveness of cancer disease, in basic research, for understanding
 the physiological function of the original TIG, in targeting or
 developing pharmaceuticals, for distinguishing various stages in the life
 cycle of the same type of cells which may be helpful for the development
 of pharmaceuticals for various cancer stages in which cell cycle is non-
 normal, for determining mutations in tumour-involved genes and in gene
 therapy. The polypeptides are useful for identifying compounds capable of
 binding to the variant product and modulating its activity and for
 modulating endothelial differentiation and proliferation, as well as to
 modulate apoptosis either ex vivo or in vivo. The sequences presented in
 ABG79700-ABG79705 are the new variants (NV) 1-36 proteins of the TIGs
 disclosed

SQ Sequence 648 AA:

Query Match	100.0%	Score	3506	DB	5;	Length	648;
Best Local Similarity	100.0%	Pred.	No.	0;	Mismatches	0;	
Matches	648;	Conservative	0;				
QY	1	MSPFRLIGLSFDCGCGCSCGCGEAMNPYCAGVNLKEYVESENQKTYKEPTMPPWDSTP	60	Db		Indels	0;
QY	1	MSPFRLIGLSFDCGCGCSCGCGEAMNPYCAGVNLKEYVESENQKTYKEPTMPPWDSTP	60	Db		Gaps	0;
QY	61	DAHINKGRVMQIVKRNVDLSESETTVELLYSIAERCRKRNGKTKIWLKLKPQSNMLMAR	120	Db			
QY	121	YFLMEDDTKDNEEFEGFALHORGATQAKVHKHEFAATPFPFCVCHFV	180	Db			
QY	121	YFLMEDDTKDNEEFEGFALHORGATQAKVHKHEFAATPFPFCVCHFV	180	Db			
QY	181	WGLNKQGYQCQNAIHKKCIIDKTAKTGSAINSRETMFKERKDMPHRKTVNYK	240	Db			
QY	181	WGLNKQGYQCQNAIHKKCIIDKTAKTGSAINSRETMFKERKDMPHRKTVNYK	240	Db			
QY	241	SPTFCRGCGTLLGJARQGKCDAGMNVRHQCKVANLGINQKLMABALAMESTQO	300	Db			
QY	241	SPTFCRGCGTLLGJARQGKCDAGMNVRHQCKVANLGINQKLMABALAMESTQO	300	Db			
QY	301	ARCLRDTEQIFREGVEIGLPCSTKNEARPPCLTPGKREPQGTWSESPPLDEVKMCLP	360	Db			
QY	301	ARCLRDTEQIFREGVEIGLPCSTKNEARPPCLTPGKREPQGTWSESPPLDEVKMCLP	360	Db			
QY	361	EPELNKKRPSIQKUKIEDTILHKMGKGSFFGKFLAERFRKTNOFFATAKLDVVMDD	420	Db			
QY	361	EPELNKKRPSIQKUKIEDTILHKMGKGSFFGKFLAERFRKTNOFFATAKLDVVMDD	420	Db			
QY	421	DVECTNVEKVLSLAWEHPRHTMCFKTKENIFFWMEYLNGDLMTHIQSCHKFDLSR	480	Db			
QY	421	DVECTNVEKVLSLAWEHPRHTMCFKTKENIFFWMEYLNGDLMTHIQSCHKFDLSR	480	Db			
QY	481	ATPYAEBITLGQFLHSK3IVYRDLKLDNILLDKGHIKADFGMKENLDAKTNFC	540	Db			
QY	481	ATPYAEBITLGQFLHSK3IVYRDLKLDNILLDKGHIKADFGMKENLDAKTNFC	540	Db			
QY	541	GTPDIAPELIGOKNSHDWWPGVLYEMLQGOSPHGQBEELHSIRMDNPYPR	600	Db			
QY	541	GTPDIAPELIGOKNSHDWWPGVLYEMLQGOSPHGQBEELHSIRMDNPYPR	600	Db			
QY	601	WLEKEAKDLVVKVRSBAKSFTIRAGLVSVFLLVSLVLUHVANDYY	648	Db			
QY	601	WLEKEAKDLVVKVRSBAKSFTIRAGLVSVFLLVSLVLUHVANDYY	648	Db			

SQ Sequence 648 AA:

RESULT 2
 ABG79678 ID ABG79678 standard; protein, 615 AA.
 XX AC ABG79678;
 XX DT 15-NOV-2002 (first entry)
 DE Tumour involved gene (TIG) splice variant protein, NV-9.
 XX Human; splice variant; tumour-involved gene; TIG;
 XX pharmaceutical composition; cancer; diagnostic; tumour; gene therapy;
 XX endothelial cell; cell differentiation; cell proliferation; apoptosis;
 XX gene therapy.
 OS Homo sapiens.
 XX PN US2002086384-A1.
 XX PD 04-JUL-2002.
 XX PR 13-MAR-2001; 2001US-00805020.
 XX PR 14-MAR-2000; 2000IL-00135402.
 XX PR 16-MAY-2000; 2000IL-00136154.
 PA <LEVI/ LEVINE Z.
 PA <DAVI/ DAVID A.
 PA (ROMA/ ROMANO C.
 PA (BERN/ BERNSTEIN J.
 XX PI Levine Z, David A, Romano C, Bernstein J;
 DR DR N-PSDB; ABG65208.
 XX PT Novel nucleic acid sequence, which is an alternative splicing variant of
 PT tumor involved genes, useful for detecting cancer, predisposition to
 PT cancer, for evaluating cancer state and in gene therapy for treating
 PT cancer.
 XX PS Claim 4; Page 73-75; 180pp; English.
 XX The invention discloses isolated human nucleic acid alternative splicing
 CC variants that are all tumour-involved genes (TIGs). The nucleic acids and
 CC polypeptides are useful for determining the level of a nucleic acid or
 CC polypeptide in a biological sample, for detecting a variant nucleic acid
 or polypeptide sequence in a biological sample, for determining the level
 of variant nucleic acid or polypeptide sequences in a biological sample
 and for determining the ratio between the level of variant sequence in a
 first biological sample and the level of the original sequence from which
 CC the variant has been varied by alternative splicing in a second
 CC biological sample and for raising antibodies. A pharmaceutical
 composition comprising a carrier and the nucleic acid, is useful for
 treating diseases (e.g. cancer) that can be ameliorated or cured by
 increasing or decreasing the level of the encoded protein. The nucleic
 acids are also useful for diagnostic purposes, especially for detecting
 cancer or a predisposition to cancer, for evaluating the state or
 aggressiveness of cancer disease, in basic research, for understanding
 the physiological function of the original TIG, in targeting or
 developing pharmaceuticals, for distinguishing various stages in the life
 cycle of the same type of cells which may be helpful for the development
 of pharmaceuticals for various cancer stages in which cell cycle is non-
 normal, for determining mutations in tumour-involved genes and in gene
 therapy. The polypeptides are useful for identifying compounds capable of
 binding to the variant product and modulating its activity and for
 modulating endothelial differentiation and proliferation, as well as to
 modulate apoptosis either ex vivo or in vivo. The sequences presented in
 disclosed

SQ Sequence 615 AA:

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model.

Run on: March 25, 2004, 16:38:50 ; Search time 952 Seconds
(w/out alignments)
10508.935 Million cell updates/sec

Title: US-09-805-020-36
Perfect score: 2355
Sequence: 1 gaattccggcagccccca.....ctccaaacaaataaggga 2355

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_29Jan04:
1: geneseqn1980s:
2: geneseqn1990s:
3: geneseqn2000s:
4: geneseqn2001as:
5: geneseqn2001bs:
6: geneseqn2002as:
7: geneseqn2003as:
8: geneseqn2003bs:
9: geneseqn2003cs:
10: geneseqn2004as:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match %	Length	DB ID	Description
1	2355	100.0	2355	6	AB65235	Abs65235 cDNA, enco
2	2331	99.0	2369	6	AB65208	Abs65208 cDNA, enco
3	1927.2	81.8	2754	4	AAT59810	Aaf59810 Human pro
4	1927.2	81.8	2754	4	AAT59810	Aaf59810 Human pro
5	1927.2	81.8	2754	6	AB167085	Ab167085 Thyroid c
6	1927.2	81.8	2754	6	AC085477	Acc85477 Human pro
7	1857.4	78.9	2754	9	ADD84903	Ade84903 Farmerly
8	1857.4	78.9	2705	3	AAD35299	Aaa35299 Human ade
9	1857.4	78.9	2705	5	AAR21421	Aaf21421 Human low
10	1857.4	78.9	2705	7	AAR42213	Aah42213 Nucleotide
11	1857.4	78.9	2705	7	ABZ97115	Abz97115 Human nuc
12	1857.4	78.9	38644	3	AAL35302	Abz22924 Human pro
13	1857.4	78.9	38644	3	AAR21424	Aaa35002 Human ade
14	1857.4	78.9	38644	7	ABZ97118	Aaf21424 Human low
15	1850.4	78.6	2659	5	AAT42214	Abz97118 Human nuc
16	1836.4	78.0	2121	6	ABV78235	Aah42214 Nucleotide
17	1836.4	78.0	2121	6	ABX35811	Abv78235 Human PKC
18	1836.4	78.0	2121	6	ABX10054	Abx35811 Human PKC
19	1836.4	78.0	2121	6	ABU91776	Abx10054 Human PKC
20	685.8	29.1	2909	2	AAP01758	Abu91776 Human pol
21	685.8	29.1	2909	7	ABP41763	Aap01758 CDNA sequ
22	685.8	29.1	2909	9	ABD53627	Abt41763 Toxicity
23	682.6	29.0	2891	2	AAP257016	Abd53627 Primary
24						Aaa35290 Human ade
25						Aat21412 Human low
26						Aac8422 Human pro
27						Abz97106 Human nuc
28						Abv78229 Human PKC
29						Abx35805 Human PKC
30						Abx10048 Human PKC
31						Abi91770 Human pol
32						Aaa35289 Human ade
33						Aaf21411 Human low
34						Abk3588 Human cDN
35						Abz97105 Human nuc
36						Aaa35292 Human ade
37						Aaf21414 Human low
38						Abz97108 Human nuc
39						Asd57014 PKC epsilon
40						Ad50078 Protein
41						Aad59551 Mouse pro
42						Aaa35293 Human ade
43						Arf21415 Human low
44						Aai48609 Human ins
45						Abz97109 Human nuc

ALIGNMENTS

RESULT 1	ID	ABS65235	standard; cDNA; 2355 BP.
XX	XX	XX	XX
XX	XX	XX	XX
DT	15-NOV-2002	(first entry)	XX
XX	XX	XX	XX
DB	cDNA encoding tumour involved gene (TIG) splice variant, NV-36.	XX	XX
KW	Human; ss; gene; Splice variant; tumour-involved gene; TIG;	XX	XX
KW	pharmaceutical composition; cancer; diagnostic; tumour; gene therapy;	XX	XX
KW	endothelial cell; cell differentiation; cell proliferation; apoptosis;	XX	XX
KW	gene therapy.	XX	XX
OS	Homo sapiens.	XX	XX
XX	US2002086384-A1.	XX	XX
XX	US2002086384-A1.	XX	XX
PD	04-JUL-2002.	XX	XX
PP	13-MAR-2001; 2001HS-00805020.	XX	XX
PR	14-MAR-2000; 2000IL-00135402.	XX	XX
PR	16-MAY-2000; 2000IL-00136154.	XX	XX
PA	{LEV/} LEVINE Z.	PA	PA
PA	(DAV/)	DAVID A.	DAVID A.
PA	(ROMA/)	ROMANO C.	ROMANO C.
PA	(BERN/)	BERNSTEIN J.	BERNSTEIN J.
PI	Levine Z, David A, Romano C, Bernstein J;	PI	PI
XX	WPI: 2002-635679/08.	DR	DR
DR	P-PSDB; ABG79705.	DR	DR
PT	Novel nucleic acid sequence, which is an alternative splicing variant of tumor involved genes, useful for detecting cancer, predisposition to cancer, for evaluating cancer state and in gene therapy for treating cancer.	PT	PT
CC	The invention discloses isolated human nucleic acid alternative splicing variants that are all tumour-involved genes (tigs). The nucleic acids and polypeptides are useful for determining the level of a nucleic acid or	CC	CC

Claim 1; Page 64-65; 180pp; English.

CC polypeptide in a biological sample, for detecting a variant nucleic acid or polypeptide sequence in a biological sample, for determining the level of variant nucleic acid or polypeptide sequences in a biological sample and for determining the ratio between the level of variant sequence in a first biological sample and the level of the original sequence from which the variant has been varied, by alternative splicing in a second biological sample and for raising antibodies. A pharmaceutical composition comprising a carrier and the nucleic acid is useful for treating diseases (e.g. cancer) that can be ameliorated or cured by increasing or decreasing the level of the encoded protein. The nucleic acids are also useful for diagnostic purposes, especially for detecting cancer or a predisposition to cancer, for evaluating the state or aggressiveness of cancer disease, in basic research, for understanding the physiological function of the original TIG, in targeting or developing pharmaceuticals, for distinguishing various stages in the life cycle of the same type of cells which may be helpful for the development of pharmaceuticals for various cancer stages in which cell cycle is non-normal, for determining mutations in tumour-involved genes and in gene therapy. The polypeptides are useful for identifying compounds capable of binding to the variant product and modulating its activity and for modulating atherosclerosis either ex vivo or in vivo. The sequences presented in AB652200-AB65235 are the coding sequences for the new variants (IV) 1-36 of the TIGs disclosed.

Sequence 2355 BP; 667 A; 537 C; 594 G; 557 T; 0 U; 0 Other;
 Best Local Similarity 100 %; Score 2355; DB 6; Length 2355;
 Matches 2355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAAATTCGGCAACCCGCAATCCCGCGCAGTCCCGCGAGGCCAACCGGC 60
 Db 1 GAAATTCGGCAACCCGCAATCCCGCGCAGTCCCGCGAGGCCAACCGGC 60
 QY 61 AGCAGCGCGCGCGCGCTCGCCAGGGCAACCATGTCGAGCTCGTCCG 120
 Db 61 AGCAGCGCGCGCGCGCTCGCCAGGGCAACCATGTCGAGCTCGTCCG 120
 QY 121 GTCCAACTTTGACTCGGGCTCTCGAGCTTGAGGGGGCTGTAAACCTAG 180
 Db 121 GTCCAACTTTGACTCGGGCTCTCGAGCTTGAGGGGGCTGTAAACCTAG 180
 QY 181 TGCCTGCTCTGCAAGAGATGTGCAATGAGACGGAGCACTTGTGAGT 240
 Db 181 TGCCTGCTCTGCAAGAGATGTGCAATGAGACGGAGCACTTGTGAGT 240
 QY 241 GCCTTACATGTAACCCACCTGGACAGCACTTGTGAGCATACTGAGAAGT 300
 Db 241 GCCTTACATGTAACCCACCTGGACAGCACTTGTGAGCATACTGAGAAGT 300
 QY 301 CATGAGATCTTGAAAGSCAAGACGGACTTGTGAGCATTCACAGGAGCT 360
 Db 301 CATGAGATCTTGAAAGSCAAGACGGACTTGTGAGCATTCACAGGAGCT 360
 QY 361 CTACTCGCTGCTGAGAGGGCAAGAGAACCGGAAGACAAGAATATGGTAGCT 420
 Db 361 CTACTCGCTGCTGAGAGGGCAAGAGAACCGGAAGACAAGAATATGGTAGCT 420
 QY 421 GAAACTCAAGCCGATGTAAGATCAAGTACTTCTGAAATAGGAGACMA 480
 Db 421 GAAACTCAAGCCGATGTAAGATCAAGTACTTCTGAAATAGGAGACMA 480
 QY 481 GAGATGAAATGAGGGAGGCTCTTGCTGAGCATCGCCGGGGTGCT 540
 Db 481 GAGATGAAATGAGGGAGGCTCTTGCTGAGCATCGCCGGGGTGCT 540
 QY 541 CAAGCGGGAAAGTCACACGTCAGTCGCACTGCACTGCACTGCACTGCA 600
 Db 541 CAAGCGGGAAAGTCACACGTCAGTCGCACTGCACTGCACTGCACTGCA 600
 QY 601 GCCCAAGTTGCTCTGCCAACGAGTTGTCTGGGSCCTGACAAACAGGGCTACCA 660
 Db 601 GCCCAAGTTGCTCTGCCAACGAGTTGTCTGGGSCCTGACAAACAGGGCTACCA 660

Db 661 GTCGGAAATGCAATGCAAGGATTCACAGAAGTGTATGATAAGTATGAAATG 720
 QY 721 CACAGGATCAGTCTATGATGAGGAAACATGTCACAGGAGATGATGAGTATGAGT 720
 Db 721 CACAGGATCAGTCTATGATGAGGAAACATGTCACAGGAGATGATGAGTATGAGT 720
 QY 781 CATGCCACACGATTAAAGCTACATACAGAAGGCTACAGAAGGCTACAGTGTG 840
 Db 781 CATGCCACACGATTAAAGCTACATACAGAAGGCTACAGAAGGCTACAGTGTG 840
 QY 841 GACCTCTGTGGGACTGCGACGCGAAGACTCAGTGTGATGATGATGCGATGA 900
 Db 901 GCACTATGAGGAGGTCCACCTTGCCATAACGAGCTTGCCAACTTGTGAGCT 900
 QY 961 TGAAGCCTGGCATGATGAGACTCAAAGGGCTGTAAAGGATACGTGACA 1020
 Db 961 TGAAGCCTGGCATGATGAGACTCAAAGGGCTGTAAAGGATACGTGACA 1020
 QY 1021 GATCTCAGAGAGGGTCCGATGAGACTCAAAGGGCTGTAAAGGATACGTGACA 1080
 Db 1021 GATCTCAGAGAGGGTCCGATGAGACTCAAAGGGCTGTAAAGGATACGTGACA 1080
 QY 1081 GCGCCATGTTACCAACCGGGAAAAGAGGCTCGGGCATTCTGGGAGTC 1140
 Db 1081 GCGCCATGTTACCAACCGGGAAAAGAGGAGCTCGGGCATTCTGGGAGTC 1140
 QY 1141 GTTGGAGAGGTGATAAATGGCAGACTCTCCAGAACACTGAAAGAAC 1200
 Db 1141 GTTGGAGAGGTGATAAATGGCAGACTCTCCAGAACACTGAAAGAAC 1200
 QY 1201 ATCTCTGAGTTAACTTAAATGGATTATCTCACAAATATGGGAAAG 1260
 Db 1201 ATCTCTGAGTTAACTTAAATGGATTATCTCACAAATATGGGAAAG 1260
 QY 1261 AAGTTGGCAGGCTTCTGGAGATTCAGAAACCAATCAATTTCGCTATA 1320
 Db 1261 AAGTTGGCAGGCTTCTGGAGATTCAGAAACCAATCAATTTCGCTATA 1320
 QY 1321 GGCCTTAAGAAAGATGGCTGTGAGGAGATGAGTGTGAGTGTGAGT 1380
 Db 1321 GGCCTTAAGAAAGATGGCTGTGAGGAGATGAGTGTGAGTGTGAGT 1380
 QY 1381 GAGAGTCTTCTGGCTGGAGGATCGTTCTGAGGACATGTTGTGACATCCA 1440
 Db 1381 GAGAGTCTTCTGGCTGGAGGATCGTTCTGAGGACATGTTGTGACATCCA 1440
 QY 1441 GACCAAGGAAACCTTCTGGAGGATCCACAGGGGGCTAATGACAA 1500
 Db 1441 GACCAAGGAAACCTTCTGGAGGATCCACAGGGGGCTAATGACAA 1500
 QY 1501 CATCCAAAGCTGCCAACAGTGTGACCTTCTGAGGAGCTTATGCTGAAATCT 1560
 Db 1501 CATCCAAAGCTGCCAACAGTGTGACCTTCTGAGGAGCTTATGCTGAAATCT 1560
 QY 1561 TCTGGCTGCTGCTCATTCAGAAGGATACTCTAGGAGACCTAAGGAGATA 1620
 Db 1561 TCTGGCTGCTGCTCATTCAGAAGGATACTCTAGGAGACCTAAGGAGATA 1620
 QY 1621 CATCCAAAGCTGCCAACAGTGTGACCTTCTGAGGAGCTTATGCTGAAATCT 1680
 Db 1621 CATCCAAAGCTGCCAACAGTGTGACCTTCTGAGGAGCTTATGCTGAAATCT 1680
 QY 1681 CATGTTAGGAGGAGAATGACTCTCTGAGGAGCTGACTAATGCCAGA 1740
 Db 1681 CATGTTAGGAGGAGAATGACTCTCTGAGGAGCTGACTAATGCCAGA 1740

GenCore version 5.1.6
 Copyright (c) 1993 - 2004 Compugen Ltd.

Score greater than or equal to the score of the result being printed,
 and is derived by analysis of the total score distribution.

SUMMARES

Result No.	Score	Query Match Length	DB ID	Description
1	1930.4	82.0	3292 6 AX780110	AX780110 Sequence
2	1927.2	81.8	2754 6 AR130752	AR130752 Sequence
3	1927.2	81.8	2754 6 AX334913	AX334913 Sequence
4	1927.2	81.8	2754 6 AX774806	AX774806 Sequence
5	1927.2	81.8	2754 9 HUMPKC	L01087 Human proteo
6	1857.4	78.9	2705 9 AX481505	L07032 Human proteo
7	1836.4	78.0	2121 6 HSM807803	AX41505 Sequence
8	1834.8	77.9	3370 9 MUSPKCT	BX67657 Homo sapi
9	1834.5	62.6	3313 10 MUSPKCT	D110911 Mouse mRNA
10	1813.8	34.6	2184 10 AB06122	AB06122 Mus muscu
11	1743.6	31.1	2977 10 AF219629	AF219629 Rattus sp
12	1712.6	30.2	2891 6 A37237	AB011812 Mus muscu
13	1691.2	29.3	2538 10 MNPKCD	X60334 M.musculus
14	1690.2	29.3	2564 10 MUSPKCD	M93042 Mouse proteo
15	1686.2	29.1	2693 9 AF251036	AF251036 Mus muscu
16	1685.8	29.1	2909 6 E02147	E02147 Rat protein
17	1685.8	29.1	2909 10 RATERKDA	AB011812 Mus muscu
18	1684.2	29.1	2891 6 BD262869	AB011812 Mus muscu
19	1680.2	28.9	2059 5 AB105739	AB105739 Xenopus laevis
20	1677.4	28.8	2100 5 AB105740	AB105740 Xenopus laevis
21	1673.6	28.6	2693 9 BC043350	BC043350 Homo sapi
22	1671.8	28.5	2104 9 HUMPKCD13X	LO7861 Human proteo
23	1670.2	28.5	2104 6 AR135354	AR135354 Sequence
24	1670.2	28.5	2104 6 BD262869	BD262869 Antisense
25	1670.2	28.5	2104 6 AR380646	AR380646 Sequence
26	1670.2	28.5	2104 6 AX771580	AX771580 Sequence
27	1670.2	28.5	2104 6 AX779795	AX779795 Sequence
28	1670.2	28.5	2104 9 HUMPKCD13X	LO7861 Human proteo
29	1664.4	28.2	2031 12 AY335687	AY335687 Synthetic sequence
30	1664.4	28.2	2031 12 AY335687	AY335687 Synthetic sequence
31	1634.2	26.9	2918 5 BC043327	BC043327 Danio rerio
32	1632.4	26.9	2632 9 HUMPKCD	DI0495 Homo sapien
33	1632.4	26.9	2163 9 AL137145	AL137145 Human DNA
34	1630.4	25.1	137072 9 AL35893	AL35893 Homo sapi
35	1630.4	25.1	1848 9 AK130150	AK130150 Homo sapi
36	1630.2	22.6	5932 9 BC051416	BC051416 Mus muscu
37	1629.2	21.2	2517 10 BC051416	BC051416 Mus muscu
38	1629.4	16.5	3891.4 16.5 3455 3 SRNPCKSR	Y13103 S.raphanus
39	1629.4	16.5	3891.4 16.5 3455 3 SRNPCKSR	222521 R.sapiens P
40	1629.4	16.0	376 16.0 2235 10 AF028009	AF028009 Mus muscu
41	1629.4	16.0	375 16.0 2235 10 AF028009	AF028009 Mus muscu
42	1629.4	15.9	374.4 15.9 2274 6 AR282728	AF325507 Mus muscu
43	1629.4	15.9	374.4 15.9 2274 6 AR282728	AR282728 Sequence
44	1629.4	15.8	372.8 15.8 2704 6 E02148	X55293 R.sapiens m
45	1629.4	15.8	372.8 15.8 2704 10 RATPKCA	B03148 Rat protein
				M18331 Rat protein

ALIGNMENTS

RESULT 1
 AX780110 LOCUS Sequence 2267 from Patent WO0339443.
 DEFINITION Sequence 2267 from Patent WO0339443.
 ACCESSION AX780110
 VERSION AX780110.1 GI:32697104
 KEYWORDS SOURCE
 ORGANISM Homo sapiens (human)
 Homo sapiens
 Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE I
 AUTHORS Haferlach, T., Schoch, C., Kern, W., Kohlmann, A., Schmittger, S.,
 Dugas, M., Ellis, R., Brors, B. and Mergenthaler, S.
 TITLE Novel genetic markers for leukemias
 Pred. No. is the number of results predicted by chance to have a

JOURNAL Patent: WO 03039443-A 2267 15-MAY-2003;
 Deutches Krebsforschungszentrum (DE);
 Ludwig-Maximilian-Universitaet Muinch (DE); Haerlach, Torsten,
 PD Dr. Dr. (DE); Schoch, Claudia (DE); Kern, Wolfgang (DE)
 FEATURES source
 location/Qualifiers
 1..3392
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

ORIGIN

Query Match Score 1930.4; DB 6; Length 3292;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 1931; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GAARTCCGCGAGCCGCCAGTCCCGGGCAGTCCAGCCACGGGG 60
 Db 1 GAATTCGCGCAACCCGCAGTCGGCGCAATCCCGCGAGTCCAGCCACGGGG 60
 QY 61 AGCAGGGGGCGCTGCTCCAGGGGCAACATGCGGATTCTTCGATGCTT 120
 Db 61 AGCGCGGGCGCCAGCTCTCCAGGGGCAACATGCGGATTCTTCGATGCTT 120
 Db 61 AGCGCGGGCGCCAGCTCTCCAGGGGCAACATGCGGATTCTTCGATGCTT 120
 QY 121 GTCCAACTTGACTGGGGCTCTGCCAGTCGTGTCAGGGGGCTTAACCTACTG 180
 Db 121 GTCCAACTTGACTGGGGCTCTGCCAGTCGTGTCAGGGGGCTTAACCTACTG 180
 QY 181 TGCCTGCTGCTCAAAAGAGTATGTCGAATCAGAAGACGGGAGATGATACTCAGAAAA 240
 Db 181 TGCCTGCTGCTCAAAAGAGTATGTCGAATCAGAAGACGGGAGATGATACTCAGAAAA 240
 QY 241 GCCTTACCATGACCCCTGGGACGACTTTGATGCCATCACACGGAGT 300
 Db 241 GCCTTACCATGACCCCTGGGACGACTTTGATGCCATCACACGGAGT 300
 QY 301 CATCGAGATCATGTGAAAGGAAACGTGACCTCATCTGAAACCACCGTGGACT 360
 Db 301 CATCGAGATCATGTGAAAGGAAACGTGACCTCATCTGAAACCACCGTGGACT 360
 QY 361 CTACTCGCTGTCTGAGAGGTCAGAACGGGAGACAGAACGGGAGACAGAACGGAGT 420
 Db 361 CTACTCGCTGTCTGAGAGGTCAGAACGGGAGACAGAACGGGAGACAGAACGGAGT 420
 QY 421 GAACTCAAGGCCAATGCTATGTCAGATCTCTTCTGAAATGAGGACAAA 480
 Db 421 GAACTCAAGGCCAATGCTATGTCAGATCTCTTCTGAAATGAGGACAAA 480
 QY 481 GACAGTGAATTTGAGAAGGGAGCTCTTGTCTGAAATGAGGACAAA 540
 Db 481 GACAGTGAATTTGAGAAGGGAGCTCTTGTCTGAAATGAGGACAAA 540
 QY 541 CAAGCAGGCAAGGGTCCACACGGTCAGTCAGTCAGGAGTCAGGCCACCTCTCCACA 600
 Db 541 CAAGCAGGCAAGGGTCCACACGGTCAGTCAGGAGTCAGGCCACCTCTCCACA 600
 QY 601 GCCCCATTTGCTGTCTGCCAGAGTTGTCTGGGGCCCTGACAAACAGGCTTCA 660
 Db 601 GCCCCATTTGCTGTCTGCCAGAGTTGTCTGGGGCCCTGACAAACAGGCTTCA 660
 QY 661 GTGCCGACAACTGCAATGCCAGAACCTGACAGAGTTGTCTGGGGCCCTGACAAACAGGCTTCA 720
 Db 661 GTGCCGACAACTGCAATGCCAGAACCTGACAGAGTTGTCTGGGGCCCTGACAAACAGGCTTCA 720
 QY 721 CACAGCATGCTATCAATGCCAGAACCTGACAGAGTTGTCTGGGGCCCTGACAAACAGGCTTCA 780
 Db 721 CACAGCATGCTATCAATGCCAGAACCTGACAGAGTTGTCTGGGGCCCTGACAAACAGGCTTCA 780
 QY 781 CATGCCACAGGATTAAGCTCAATACAAAGGCCGACCTCTGTGAACTGTGG 840
 Db 781 CATGCCACAGGATTAAGCTCAATACAAAGGCCGACCTCTGTGAACTGTGG 840
 QY 841 GACCTGCTGCTGGGGACTGGGACGGGAGAGCTGATGATGATGATGATGATG 900
 Db 841 GACCTGCTGCTGGGGACTGGGACGGGAGAGCTGATGATGATGATGATGATG 900

Db 901 GCACTATAGATGCCAGACAAAGTCGCAACCTTGTGCGATAAACCGAGATAATGCG 960
 QY 901 GCACTATAGATGCCAGACAAAGTCGCAACCTTGTGCGATAAACCGAGATAATGCG 960
 Db 961 TAAGGCTGCCATGATGAGGAGCACTAACAGGCTGGCTGTTAAGAGATACTGACCA 1020
 QY 961 TAAGGCTGCCATGATGAGGAGCACTAACAGGCTGGCTGTTAAGAGATACTGACCA 1020
 Db 961 TGAAGGCTGCCATGATGAGGAGCACTAACAGGCTGGCTGTTAAGAGATACTGACCA 1020
 QY 1021 GATCUTCAGAGAAGSTCCCGTGAATGCTCTCCATCTCCATCACAAAGGAGAG 1080
 Db 1021 GATCUTCAGAGAAGSTCCCGTGAATGCTCTCCATCTCCATCACAAAGGAGAG 1080
 QY 1081 GCGGCATTTAACGACACCCGGAAAGAGAGACGCTGAGGGATTCTGGAGTCCTC 1140
 Db 1081 GCGGCATTTAACGACACCCGGAAAGAGAGACGCTGAGGGATTCTGGAGTCCTC 1140
 QY 1141 GTTGGATGAGGTGGATAAATGTCCTCATTCAGAAACCTGAACTGAAAGAAGAC 1200
 Db 1141 GTTGGATGAGGTGGATAAATGTCCTCATTCAGAAACCTGAACTGAAAGAAGAC 1200
 QY 1201 ATCTTGAGATTAACAUAAATGAGCATTTATCTGCAAAAGTTGGGAAGAG 1260
 Db 1201 ATCTTGAGATTAACAUAAATGAGCATTTATCTGCAAAAGTTGGGAAGAG 1260
 QY 1261 AAGTTTGCGAAGGCTCTCTGCGAGAAATCAGAAGAACCAAATTTCCCAATAA 1320
 Db 1261 AAGTTTGCGAAGGCTCTCTGCGAGAAATCAGAAGAACCAAATTTCCCAATAA 1320
 QY 1321 GGCCTTAAGAAAGATGTGCTGATGAGCAGTGTGAGTGTGAGCTGATGGTAGACA 1380
 Db 1321 GGCCTTAAGAAAGATGTGCTGATGAGCAGTGTGAGTGTGAGCTGATGGTAGACA 1380
 QY 1381 GAGAGTCTTCCTGGGAGCATGCTGTTGAGGACATGTTGTTTGACATG 1440
 Db 1381 GAGAGTCTTCCTGGGAGCATGCTGTTGAGGACATGTTGTTTGACATG 1440
 QY 1441 GACCAAGAAACCTCTTTTGTGATGAGGAGCTTCAAGGAGGGACATTAATGACCA 1500
 Db 1441 GACCAAGAAACCTCTTTTGTGATGAGGAGCTTCAAGGAGGGACATTAATGACCA 1500
 QY 1501 CATCCAAGCTGCCACAACTGACCTTCAAGGAGGGACATTAATGACCA 1560
 Db 1501 CATCCAAGCTGCCACAACTGACCTTCAAGGAGGGACATTAATGACCA 1560
 QY 1561 TCTTGTCTGCAAGGATCTTCAATCCAAAGAAATGAGTCCTCAAGGAGGACTTAATGAGATA 1620
 Db 1561 TCTTGTCTGCAAGGATCTTCAATCCAAAGAAATGAGTCCTCAAGGAGGACTTAATGAGATA 1620
 QY 1621 CATCCCTGTCAGACAGGATGACATTCAGATGAGGAGCTTCAAGGAGGGCTTCAAGGAGGAGTTCAGGAGA 1680
 Db 1621 CATCCCTGTCAGACAGGATGACATTCAGATGAGGAGCTTCAAGGAGGGCTTCAAGGAGGAGTTCAGGAGA 1680
 QY 1681 CATGTTGAGATGCCAGAGAATACCTCTGCTGGAGACCTGACTACATGCCCAAGA 1740
 Db 1681 CATGTTGAGATGCCAGAGAATACCTCTGCTGGAGACCTGACTACATGCCCAAGA 1740
 QY 1741 GACCTGCTGGTCAAGAAACGACACTCTGCTGGAGACCTGACTACATGCCCAAGA 1800
 Db 1741 GACCTGCTGGTCAAGAAACGACACTCTGCTGGAGACCTGACTACATGCCCAAGA 1800
 QY 1801 TTATGAAATGCTGATGTCAGTCGGCTTCAAGGAGGATGAGGAGGACTCTCA 1860
 Db 1801 TTATGAAATGCTGATGTCAGTCGGCTTCAAGGAGGATGAGGAGGACTCTCA 1860
 QY 1921 TCTGGTGAAGT 1932
 Db 1921 TCTGGTGAAGT 1932